CMS Claims Too Much Authority Over Medicare Rx Prices – PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services incorrectly interprets the Medicare Modernization Act to allow "justification of aggregate price levels for groups of drugs," PhRMA asserts in comments on CMS' proposed Part D regs.